Denali Therapeutics (NASDAQ:DNLI) Now Covered by Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft started coverage on shares of Denali Therapeutics (NASDAQ:DNLI) in a research note published on Tuesday, Marketbeat Ratings reports. The brokerage issued a buy rating and a $31.00 target price on the stock.

DNLI has been the subject of a number of other reports. The Goldman Sachs Group reduced their price target on shares of Denali Therapeutics from $45.00 to $40.00 and set a “buy” rating for the company in a research report on Tuesday, January 28th. Stifel Nicolaus raised shares of Denali Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 price objective on the stock in a research note on Monday, December 16th. Robert W. Baird began coverage on shares of Denali Therapeutics in a research note on Tuesday, January 7th. They set an “outperform” rating and a $31.00 price objective on the stock. Baird R W raised shares of Denali Therapeutics to a “strong-buy” rating in a research note on Tuesday, January 7th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Denali Therapeutics from $28.00 to $24.00 and set an “overweight” rating on the stock in a research note on Tuesday, January 7th. Two equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Denali Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $37.42.

Denali Therapeutics Trading Down 1.4 %

DNLI opened at $20.58 on Tuesday. Denali Therapeutics has a 12-month low of $14.56 and a 12-month high of $33.33. The firm has a market capitalization of $2.96 billion, a PE ratio of -7.46 and a beta of 1.43. The firm has a 50 day moving average of $22.03 and a two-hundred day moving average of $24.79.

Insiders Place Their Bets

In other news, CEO Ryan J. Watts sold 29,266 shares of the business’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $20.22, for a total transaction of $591,758.52. Following the completion of the transaction, the chief executive officer now directly owns 260,721 shares of the company’s stock, valued at approximately $5,271,778.62. The trade was a 10.09 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Vicki L. Sato sold 3,080 shares of the business’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $20.91, for a total value of $64,402.80. Following the transaction, the director now directly owns 107,976 shares of the company’s stock, valued at approximately $2,257,778.16. This represents a 2.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 47,940 shares of company stock valued at $973,442 in the last 90 days. 7.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Denali Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in DNLI. FMR LLC raised its position in Denali Therapeutics by 3,234.3% in the third quarter. FMR LLC now owns 7,831,378 shares of the company’s stock worth $228,128,000 after acquiring an additional 7,596,508 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Denali Therapeutics by 63.2% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,749,486 shares of the company’s stock valued at $109,223,000 after acquiring an additional 1,451,770 shares during the last quarter. Wellington Management Group LLP boosted its stake in shares of Denali Therapeutics by 9.2% during the third quarter. Wellington Management Group LLP now owns 10,727,450 shares of the company’s stock valued at $312,491,000 after acquiring an additional 903,683 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Denali Therapeutics by 7.6% during the fourth quarter. Vanguard Group Inc. now owns 12,021,230 shares of the company’s stock valued at $244,993,000 after acquiring an additional 843,996 shares during the last quarter. Finally, Segall Bryant & Hamill LLC acquired a new stake in shares of Denali Therapeutics during the fourth quarter valued at $5,891,000. Hedge funds and other institutional investors own 92.92% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.